Establishment Labs (ESTA) Set to Announce Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) is scheduled to be announcing its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.61) per share for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Establishment Labs (NASDAQ:ESTA) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). The business had revenue of $44.12 million for the quarter, compared to analyst estimates of $43.10 million. Establishment Labs had a negative return on equity of 220.67% and a negative net margin of 54.97%. Establishment Labs’s quarterly revenue was down 9.2% compared to the same quarter last year. During the same period last year, the firm earned ($0.65) EPS. On average, analysts expect Establishment Labs to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Establishment Labs Price Performance

Shares of NASDAQ ESTA opened at $47.90 on Wednesday. The business’s 50 day moving average price is $43.25 and its two-hundred day moving average price is $45.89. The company has a market cap of $1.34 billion, a PE ratio of -15.40 and a beta of 1.20. The company has a quick ratio of 2.91, a current ratio of 4.44 and a debt-to-equity ratio of 4.30. Establishment Labs has a twelve month low of $16.96 and a twelve month high of $60.12.

Analyst Upgrades and Downgrades

ESTA has been the topic of a number of recent analyst reports. Stephens reissued an “overweight” rating and set a $68.00 price target on shares of Establishment Labs in a research report on Wednesday, August 7th. BTIG Research boosted their price target on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. Citigroup boosted their price target on Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 1st. Finally, JPMorgan Chase & Co. reduced their price objective on Establishment Labs from $61.00 to $50.00 and set an “overweight” rating for the company in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, Establishment Labs has a consensus rating of “Moderate Buy” and a consensus target price of $58.83.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.